6048 results for "canc*"

in 48.04 milliseconds.

• Childhood Cancer Data Initiative (CCDI): CCDI Pediatric In Vivo Testing Program - Orthotopic CNS Tumors

  The goal of this project is to advance the development of effective therapies for pediatric brain cancers through preclinical in vivo testing of novel agents. We utilize a well-characterized panel of approximately 150 patient-derived orthotopic xenograft (PDOX) models that replicate the histopathologic and molecular features of the original patient tumors. These models represent multiple pediatric CNS tumor types, including high-grade glioma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma (DIPG), and atypical teratoid/rhabdoid tumor (ATRT), across diverse disease stages and molecular subtypes. As part of this effort, the PDOX models are being molecularly characterized to identify promising therapeutic candidates. Molecular profiling includes whole exome sequencing (WES), RNA-seq, MethylEPIC array, CytoSNP array, and DNA fingerprinting for quality control. Demographic and clinical data (e.g., diagnosis, disease site, disease status) are also shared.

  Study phs003162

• Kids First: Childhood Cancer Data Initiative (CCDI) - Discovering the Timing and Origins of Bone and Soft Tissue Cancers

  Sarcoma are cancers of bone and connective tissue that disproportionately affect children and are often difficult to diagnose. This study presents the genome and transcriptome sequences of carefully curated sarcoma tumors and matched non-neoplastic (normal) specimens including a cohort of benign bone and soft tissue tumors, totalling 1122 sequences from 310 participants, covering 69 various subtypes. High-quality pathology reviewed specimens (FF or FFPE) with detailed clinical data were selected to inform key temporal landmark in sarcoma development – from tumor initiation to the generation of critical oncogenic fusions and malignant potential, to possible relapse or metastasis.

  Study phs002827

• NCTN: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor (AREN0532)

  Study ID: AREN0532NCT Numbers: NCT00352534Children's Oncology GroupSubmitted in collaboration with the NCTN/NCORP Data ArchiveTrial Title: NCTN: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor (AREN0532)Trial Description: This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.Clinical data presented in the following publication(s):PMID 27811504PMID 29211618Disease type(s): Kidney Neoplasm - Wilms TumorClinical Dataset(s) included:NCT00352534-D1 (PMID 27811504): There is one dataset (-D1) for the AREN0532 primary publication 27811504, reporting on the trial's very low-risk cohort. This dataset contains baseline characteristics, WT1 mutation status, loss of heterozygosity, relapse sites, presence of intralobar and perilobar rests, survival, secondary malignancy, and radiotherapy type data.NCT00352534-D2 (PMID 29211618): There are two datasets (-D2 and -D3) for the AREN0532 primary publication 29211618, reporting on patients with stage III favorable-histology Wilms tumor. There is one row for each patient enrolled. The dataset contains the data for the consort flow of patient enrollment, baseline characteristics, surgery details, 1p/16q loss of heterozygosity status, second malignant neoplasm, survival, relapse site, grade of adverse events, and tumor status data for the patients on AREN0532 as reported in the manuscript.NCT00352534-D3 (PMID 29211618): There are two datasets (-D2 and -D3) for the AREN0532 primary publication 29211618, reporting on patients with stage III favorable-histology Wilms tumor. This dataset contains EFS and OS data for patients enrolled on the Q9401 study described in the manuscript to compare outcomes for patients on AREN0532 to similar patients on Q9401 who received the same therapy.Select data from Q9401 (NCT00002611) used in AREN0532 publication PMID 29211618 are contained in NCT003525234-D3.You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).

  Study phs004139

• Genomic Characterization CS-MATCH-0007 Arm C1

  The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm C1 is one of the treatment sub-protocols within the NCI-MATCH Clinical Trial (EAY131) where patients with MET amplification are treated with Crizotinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.

  Study phs002177

• MP2PRT: PI3K Pathway Activation and Its Associated Genomic Profile as Predictive Biomarkers of HPV-Related Oropharyngeal Cancer: Evaluation of NRG HN002 and RTOG 1016

  The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network. This study, titled “PI3K Pathway Activation and Its Associated Genomic Profile as Predictive Biomarkers of HPV-Related Oropharyngeal Cancer: Evaluation of NRG-HN002 and RTOG 1016”, is one of the selected studies under this program. For this study, molecular characterization (i.e., WES, Total RNAseq, and multiplex immunofluorescence staining) was performed on formalin-fixed paraffin embedded tumor tissue and matching germline previously collected from patients with HPV-related oropharyngeal cancer. This project will investigate genomic alterations within the PI3K pathway (PIK3CA and PTEN). It is hypothesized that an improved understanding of this pathway in a specific genetic context may lead to the development of novel therapies to guide future clinical trials and improve the clinical outcomes of patients with HPV-positive oropharyngeal cancer.

  Study phs003089

• Analysis of Epigenomes and Genome Topology in Colorectal Cancer

  When diagnosing cancer, pathologists use nuclear morphology as a hallmark of tumor cells, but the topological changes linked to alterations in the shape of the nucleus were poorly understood. To uncover the molecular changes that occur in the 3D structure of cancer genomes, we integrated topological maps for colon tumors and normal colon tissues with epigenetic, transcriptional, and imaging data. We characterized tumor-associated changes in chromatin loops, topologically associated domains (TADs), and large-scale compartments. We found that chromatin loop rewiring contributes to oncogenic gene expression programs. Whereas TAD structures are largely stable, the spatial partitioning of the open and closed genome compartments is compromised in tumors and is accompanied by hypomethylation and histone mark rearrangements. We also identified a compartment that is reorganized in tumors and is at the interface between the canonical A and B compartments. Similar changes were evident in non-malignant cells that had accumulated excessive cellular divisions. Our analyses suggest that these compartment changes repress stemness and invasion programs while inducing immunity genes, and they may therefore restrain malignant progression.

  Study phs002288

• NCTN: A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy (EA1131)

  Study ID: EA1131 NCT Number: NCT02445391 ECOG-ACRIN Cancer Research Group Submitted in collaboration with the NCTN/NCORP Data Archive Trial Title: NCTN: A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy (EA1131) Trial Description: This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer. Clinical data presented in the following publication(s): PMID 34092112 Disease type(s): Breast Neoplasm - Breast Cancer - Invasive Clinical dataset(s) included: NCT02445391-D1 (PMID 34092112): There are three datasets for PMID 34092112. This dataset, NCT02445391-D1, contains baseline characteristics, stratification factors, treatment, second primary cancer, cause of death and efficacy data. The data reflect the study database as of April 7, 2021. All patients who were randomized to one of the three arms were included in the database (NCT02445391-D1). Accrual was open to arm A (observation) and arm B (platinum) prior to Amendment #3, and accrual to arm A was permanently closed and accrual to arm C (capecitabine) was opened in Amendment #3. NCT02445391-D2 (PMID 34092112): There are three datasets for PMID 34092112. This dataset, NCT02445391-D2 contains data on dose modification. The data reflect the study database as of April 7, 2021. NCT02445391-D3 (PMID 34092112): There are three datasets for PMID 34092112. This dataset, NCT02445391-D3, contains toxicity data. The data reflect the study database as of April 7, 2021. All treatment-related AEs were included in the database, and only the worst degree was reported in the paper. You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).

  Study phs004236

• Long-Read Sequencing of Ovarian Cancer Organoids

  Two patient-derived organoids were derived from separate ascites fluid collections from a patient diagnosed with high-grade mullerian carcinoma, that could not be confidently subclassified based on the limited specimen. Long-read sequencing whole genome sequencing (WGS) was performed on the organoids, OC104 and OC109, using the Oxford Nanopore Technologies PromethION24 with V14 ligation kit. Information from genomic findings and further pathology on organoids suggests refining the diagnosis to mucinous ovarian carcinoma.

  Study phs004795

• Childhood Cancer Data Initiative (CCDI): Pediatric In Vivo Testing Program – Sarcomas and other Solid Tumors

  The primary goal of this project involves the comprehensive molecular profiling of patient-derived xenograft (PDX) mouse tumor models. Molecular profiling of each PDX model will include whole exome sequencing (WES), RNAseq, MethylEPIC arrays, CytoSNP array, and DNA fingerprint for quality control. Limited clinical demographic data (e.g. diagnosis, disease site, disease status) will be obtained. This data can be utilized to validate PDX models with matched patient tumors and can be used to guide model selection for downstream preclinical drug testing.

  Study phs003161

• Childhood Cancer Data Initiative (CCDI): Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the NCCR

  The goal of this study is to contribute clinical and genomic data from a large institutional cohort of pediatric cancer patients who had tumor genomic profiling between 2013 and 2019 at Dana-Farber/Boston Children's Hospital Cancer and Blood Disorders Center. Clinical data include demographics, diagnosis (classified according to the International Classification of Diseases for Oncology (ICD-O-3.2), stage, and biospecimen associated data. Tumors were sequenced with OncoPanel, a targeted next-generation DNA sequencing panel of up to 447 cancer genes for detection of single-nucleotide variants (SNV), insertions, and deletions, and copy number alterations (CNA), as well as selected intronic regions for up to 60 genes for the detection of structural variants (SV). This dataset includes a patient and sample identifier (GENIE ID) that can be used to link the genomic data included in this dataset to additional longitudinal clinical cancer data on a subset of patients that was submitted to the National Childhood Cancer Registry (NCCR).

  Study phs002677